300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Energy
Non Profit
Social Impact
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Travel
Local
Platforms
InsurTech
Film
Oil and Gas
Retail
Payments
Organic Food
Marketplace
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Biotechnology
Legal
Automotive
eSports
Renewable Energy
Software
Facebook
Blockchain
Theatre
Beauty
Fashion
Medical
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Web3
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Recruiting
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Burkina Faso
Africa
LATAM
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
New Zealand
Paraguay
Seychelles
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Bio-Rad Laboratories, VC Fund

Bio-Rad Laboratories

VC Fund

Hercules, United States

Bio-Rad Laboratories is a VC fund in Hercules focused on Health Care and Biotechnology. Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 6,500 employees and serves more than 85,000 research andindustry customers worldwide through its global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more.

Total investments:
7
Last investment:
Lead investor:
57%

Last updated:

Industries Bio-Rad Laboratories invests in

Health CareBiotechnologyGeneticsHealth DiagnosticsMedical

Stages Bio-Rad Laboratories invests in

SeedPost-IPO EquitySeries C

Countries Bio-Rad Laboratories invests in

United StatesCanadaNorwayUnited Kingdom

Contacts

NameEmailPhoneSocials
Alice Schwartz Alice Schwartz
James Stark James Stark
Kalyan Handique Kalyan Handique
Monica Niblack Monica Niblack
Norman D. Schwartz Norman D. Schwartz
See all 8 contacts →

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Health Care 3 (43%)
  • Biotechnology 3 (43%)
  • Genetics 2 (29%)
  • Health Diagnostics 2 (29%)
  • Medical 1 (14%)
See all 7 industries →

Stage

  • Seed 2 (29%)
  • Post-IPO Equity 2 (29%)
  • Series C 1 (14%)

Country

  • United States 2 (29%)
  • Canada 1 (14%)
  • Norway 1 (14%)
  • United Kingdom 1 (14%)

Team

NameTitleInvestmentsLinksEmail
Alice Schwartz
Alice Schwartz Co-Founder
Co-Founder Total investments: 0 Find email
James Stark
James Stark Vice President, Corporate Controller
Vice President, Corporate Controller Total investments: 0 Find email
Kalyan Handique
Kalyan Handique VP, CDG Advanced Technology
VP, CDG Advanced Technology Total investments: 0
Find email
Monica Niblack
Monica Niblack Business Analyst Intern
Business Analyst Intern Total investments: 0 Find email
Norman D. Schwartz
Norman D. Schwartz CEO
CEO Total investments: 0 Find email
See all 8 team members →

Investments

CompanyDescriptionRoundLinks
iMDx iMDx
iMDx is a molecular diagnostics company that develops and offers blood-based tests for oncology and transplant care. The company offers assays such as GraftAssureCore (a lab test for transplant rejection), GraftAssureIQ (a research-use kit), and DetermaIO for immunotherapy guidance. The company holds CLIA and state lab certifications. $26M / Post-IPO Equity / Feb 11, 2026
Genetic Analysis Genetic Analysis
Genetic Analysis AS (GA) has the goal of being a leader within the field of molecular diagnostics of diseases related to gut imbalances. By utilizing the DNA-based GA-map™ array technology, profiles of a patient’s gut microbiota is quickly generated and can be related to various health conditions. Genetic Analysis has developed a DNA-basedtechnology platform that allows for simultaneous analysis of a large number of similarities (but not identical) gene fragments in one reaction. The company’s focus is to utilize this technology platform to identify variations in the hundreds of different bacteria that exist in the gut (large and small intestine). The GA - map makes it possible, for the first time, to offer a diagnostic solution – including early detection - for many diseases that are affected by imbalances in the gut microbiota. Genetic Analysis will offer kits and services for a wide range of applications. $1.2M / Post-IPO Equity / May 05, 2025
Afynia Laboratories Afynia Laboratories
Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis. $5M / Seed / Feb 25, 2025
iMDx iMDx
iMDx is a molecular diagnostics company that develops and offers blood-based tests for oncology and transplant care. The company offers assays such as GraftAssureCore (a lab test for transplant rejection), GraftAssureIQ (a research-use kit), and DetermaIO for immunotherapy guidance. The company holds CLIA and state lab certifications. $29.1M / Post-IPO Equity / Feb 10, 2025
Geneoscopy Geneoscopy
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. $105M / Series C / Jan 08, 2025
iMDx iMDx
iMDx is a molecular diagnostics company that develops and offers blood-based tests for oncology and transplant care. The company offers assays such as GraftAssureCore (a lab test for transplant rejection), GraftAssureIQ (a research-use kit), and DetermaIO for immunotherapy guidance. The company holds CLIA and state lab certifications. $10.2M / Post-IPO Equity / Oct 02, 2024
Oxford Impedance Diagnostics Ltd. Oxford Impedance Diagnostics Ltd.
Oxford Impedance Diagnostics Ltd. researches, designs and will market diagnostic tests for the measurement of clinical bio markers that reduce healthcare costs and improve patient outcomes. $2.6M / Seed / Jul 25, 2016

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Energy
Non Profit
Social Impact
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Travel
Local
Platforms
InsurTech
Film
Oil and Gas
Retail
Payments
Organic Food
Marketplace
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Biotechnology
Legal
Automotive
eSports
Renewable Energy
Software
Facebook
Blockchain
Theatre
Beauty
Fashion
Medical
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Web3
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Recruiting
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Burkina Faso
Africa
LATAM
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
New Zealand
Paraguay
Seychelles
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Bio-Rad Laboratories invest in?

Bio-Rad Laboratories invests primarily in Health Care, Biotechnology and Genetics startups, most often at Seed and Post-IPO Equity stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Bio-Rad Laboratories?

Public channels for Bio-Rad Laboratories include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Bio-Rad Laboratories?

The team at Bio-Rad Laboratories includes Alice Schwartz (Co-Founder), James Stark (Vice President, Corporate Controller) and Kalyan Handique (VP, CDG Advanced Technology), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Bio-Rad Laboratories Bio-Rad Laboratories Find emails